Oncaspar Related Published Studies
Well-designed clinical trials related to Oncaspar (Pegaspargase)
A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). [2002.03]
Well-designed clinical trials possibly related to Oncaspar (Pegaspargase)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. [2002.03.15]
Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. [1999.01]
Prognostic factors for treatment of malignant lymphoma in dogs. [1994.12.15]
Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma. [1992.07]
Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma. [1990]
Other research related to Oncaspar (Pegaspargase)
FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). [2007.08]
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. [2007.04.01]
Pegaspargase: a review of clinical studies. [2003.09.26]
PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. [2002.02]
Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. [2001.04]
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. [2000.08]
Pegaspargase-induced pancreatitis. [2000.03]
Reversible MRI lesions due to pegaspargase treatment of non-Hodgkin's lymphoma. [1997.09]
Pegaspargase: an alternative? [1997.05]
Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. [1995.07]
Other possibly related research studies
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. [2005.07]
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. [2005]
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. [2004.10]
Acute lymphoblastic leukemia in a child with nephrotic syndrome. [2004.11]
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. [2004.08.15]
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. [2004.06]
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. [2003.08]
A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. [2003.07.01]
Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. [2002.10]
Minimising the long-term adverse effects of childhood leukaemia therapy. [2002]
L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. [2002.10]
Pegylation: engineering improved pharmaceuticals for enhanced therapy. [2002.04]
Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. [2001.11]
Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. [2001.08]
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. [2000.12]
[New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase] [1998]
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. [1999.10.01]
The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. [1999]
The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis. [1998.03]
Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. [1998.05]
New chemotherapy treatment options and implications for nursing care. [1997.01]
An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. [1995.03.01]
Comparative pharmacokinetic studies of three asparaginase preparations. [1993.09]
Chronic lymphocytic leukemia--correlation of response and survival. [1993]
Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey. [1993]
[Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia] [1988.05]
Development of pegylated interferons for the treatment of chronic hepatitis C. [2001]
Polymers for delivering peptides and proteins. [1994.01.15]
Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. [2006.06.01]
Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). [2006.08]
Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. [2005.11]
Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. [2006.01]
A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. [1990.02]
Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. [2007.04]
Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. [2007.03]
Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia. [2007.03]
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. [2007.05.15]
PEG-asparaginase. [2007.08]
Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. [2007.06]
Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. [2007.07.01]
Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia. [2007.03]
Predicting asparaginase-associated pancreatitis. [2007.10.15]
Ondansetron-associated hypokalemia in a 2-year-old with pre-B-cell ALL. [2008.01]
Treatment of acute lymphoblastic leukaemia : a new era. [2007]
|
